Statistical methods in pharmacoepidemiology: advances and challenges 5 from the enormous progress in pharmacogenomics and molecular biology, research that will permit to identify patients susceptible to drug risks. In all, statistical thinking and methods have been crucial in bringing methodological rigor to the study of drug effects using non-experimental methods, and are expected to continue contributing to the field of pharmacoepidemiology and its major implications on public health and clinical practice.
While the randomised controlled trial design is essential to evaluate the effectiveness and safety of medications, and to obtain regulatory approval for their use in clinical practice, it provides only partial information on their real-life effects. 1 Their study size being usually determined to assess effectiveness, these trials will only have limited ability to identify rare adverse drug reactions. Indeed, latent adverse events that only occur after long-term exposure will not be observed within the typical relatively short-term follow-up. Moreover, the large number of different adverse events evaluated introduces statistical uncertainty from multiple testing. 2 A major gap between the number of patients exposed in clinical trials and the number exposed subsequently was found for five drugs withdrawn from the US market for serious adverse drug reactions. 3 Thus, despite their proven effectiveness, the safety profile of drugs remains largely unknown at the time of marketing, so that the balance between benefit and risk is often uncertain.
In the last few decades, non-experimental observational studies have been conducted in an attempt to fill this gap with large-scale cohort and case-control studies to assess long-term drug effects on infrequent major outcomes. 4 These studies, that allow to quantify the risk of a drug, involve no intervention or intrusion besides observing the natural course of disease and its treatment longitudinally in a large patient population. This research gave rise to the field of 'pharmacoepidemiology', which can roughly be defined as the population study of the effects of drugs, and to the establishment of the International Society of Pharmacoepidemiology (ISPE: www.pharmacoepi.org). This field of research was revolutionised with the advent of computerised health databases, constituted from routinely collected administrative or clinical data, and their exploitation to study drug effects. 5, 6 Because the data are already collected, the use of such computerised health databases allow the relatively quick and inexpensive conduct of observational studies of the effects of drugs that have been on the market for some time. This has led to an explosion in the number of observational database studies of the impact of medications published in the last decade in major medical journals. As such, pharmacoepidemiology has been at the centre of major debates and controversies regarding drug safety, such as the cardiovascular and breast cancer risks with hormone replacement therapy, mortality associated with beta-agonist inhalers used in asthma, the cardiovascular risks of COX-2 inhibitors, the thrombotic risks of oral contraceptive pills, and the effects of vaccines on the risk of autism, among others.
Many applications of this approach have led to a greater appreciation of the methodological complexities in conducting observational research studies of drug effects, particularly within such databases, and the far-reaching consequences of imperfect methods. For instance, while for decades many observational studies have suggested a cardiovascular benefit with hormone replacement therapy, the large-scale Women's Health Initiative (WHI) randomised controlled trial disproved it altogether. 7−9 Another example is regarding the use of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease (COPD), with observational studies reporting important reductions in all-cause mortality with these drugs. 10−12 This apparent benefit was also refuted with the large-scale long-term TORCH randomised controlled trial that found no such benefit. 13 Another inconsistency occurred soon after the signal of an elevated cardiac risk with rofecoxib appeared from the VIGOR randomised trial, 14 two observational studies performed to assess the veracity of this risk presented discordant findings, one reporting an excess risk, the other not. 15, 16 These discordances, likely due to methodological imperfections in study design and data analysis, lead to a period of uncertainty about the safety of this drug until the risk was eventually confirmed in a randomised trial and several other observational studies. 17−21 Observational studies pharmacoepidemiology are generally subject to three sources of bias. Information bias is induced by measurement error in any of the variables, but most importantly the drug exposure or the outcome. Selection bias results from the inclusion or exclusion of subjects on the basis of factors associated with both the drug exposure and the outcome under study. Finally, confounding bias results from the imbalances in covariates between the subjects exposed to the drug under study and those in the comparison group. While randomisation balances the groups with respect to both measured and unmeasured covariates, observational studies are limited with respect to the latter, making confounding bias an important source of concern. Pharmacoepidemiology has also identified some specific forms of these biases such as protopathic bias, depletion of susceptibles, immortal time bias, and immeasurable time bias. 17,22−26 In parallel, several advances have been made in the design and analysis of pharmacoepidemiology studies.
In this themed issue on 'pharmacoepidemiology', put forward by the Editor in chief Brian Everitt, several biostatisticians and epidemiologists actively involved in this field have come together to address some of the novel advances and methodological challenges of this discipline. We tried to select a sampling of topics representative of the field and contributors who could write first-rate papers to introduce applied statisticians to this discipline with important public health implications. The papers by Hernan, Arbogast et al. and Hanley et al. present approaches to study design and data analysis to address the question of adjustment for confounding factors, a major challenge in the absence of randomisation. Farrington et al. and Delaney et al. introduce various novel withinsubject designs that are quickly becoming popular in assessing the risks of vaccines and of other medications used transiently on acute adverse outcomes. Some important topics such as propensity scores and instrumental variables were not included, but could certainly have. 27−29 Moreover, statistical challenges that lie ahead will likely involve data on the genetic make-up of patients at the population level, which will become reality
